Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2015

View Archived Issues

AbbVie presents selective P2X3 receptor antagonists for pain management

La Jolla Pharmaceutical and Vanderbilt University form agreement for BMP type-I receptor inhibitors

The Wistar Institute and OncoCyte to develop diagnostic test for lung cancer

Amgen provides early preclinical data on TRPM8 antagonist for migraine

Ocular-selective oral VEGFR-2 inhibitors for wet AMD reported by Novartis

Edge Therapeutics reports topline phase I/II NEWTON trial data

Resunab granted FDA fast track status for the treatment of systemic sclerosis

Soligenix receives additional NIAID funding to advance heat stable ricin vaccine

FDA grants fast track designation to solithromycin for CABP

Vical's VL-2397 gets FDA QIDP designation

Alkeus provides update on ALK-001 for Stargardt disease

Long-term LATTE results show HIV suppression with two-drug cabotegravir plus rilpivirine regimen

Allergan patent reports formyl peptide modulators

GlaxoSmithKline discloses LRRK2 inhibitors

Boehringer Ingelheim divulges BTK inhibitors

TP Therapeutics patent details apoptosis inducers

Janssen terminates HMPL-507 agreement with Hutchison MediPharma

FDA awards rare pediatric disease designations to idebenone and drisapersen for DMD

Prostate cancer vaccine MVI-816 enters phase I/II trial in combination with pembrolizumab

CureXcell not expected to meet primary endpoint in pivotal venous leg ulcer trial

Vernalis discloses strategy for development of V-158866

EnGeneIC begins phase I Tailored-EDV trial in solid tumors

Vivozon starts phase II trial of analgesic candidate VVZ-149

PDE10A inhibitor TAK-063 enters phase II trial in schizophrenia

Threshold's TH-4000 enters phase II trial in squamous cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...